WO2005007169A3 - Liposomes containing phosphate glycerol groups for treating acute inflammatory condition - Google Patents

Liposomes containing phosphate glycerol groups for treating acute inflammatory condition Download PDF

Info

Publication number
WO2005007169A3
WO2005007169A3 PCT/CA2004/001053 CA2004001053W WO2005007169A3 WO 2005007169 A3 WO2005007169 A3 WO 2005007169A3 CA 2004001053 W CA2004001053 W CA 2004001053W WO 2005007169 A3 WO2005007169 A3 WO 2005007169A3
Authority
WO
WIPO (PCT)
Prior art keywords
acute inflammatory
groups
inflammatory condition
liposomes containing
containing phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2004/001053
Other languages
French (fr)
Other versions
WO2005007169A2 (en
Inventor
Arkady Mandel
Anthony E Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0412882-6A priority Critical patent/BRPI0412882A/en
Priority to EA200600297A priority patent/EA200600297A1/en
Priority to MXPA06000805A priority patent/MXPA06000805A/en
Priority to EP04761575A priority patent/EP1658086A2/en
Priority to US10/565,360 priority patent/US20070238708A1/en
Priority to JP2006520639A priority patent/JP2006528136A/en
Priority to AU2004257375A priority patent/AU2004257375A1/en
Priority to CA002533084A priority patent/CA2533084A1/en
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of WO2005007169A2 publication Critical patent/WO2005007169A2/en
Publication of WO2005007169A3 publication Critical patent/WO2005007169A3/en
Priority to IL173068A priority patent/IL173068A0/en
Anticipated expiration legal-status Critical
Priority to NO20060820A priority patent/NO20060820L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G19/00—Compounds of tin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G15/00—Compounds of gallium, indium or thallium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides a method for prophylaxis or treatment of an acute inflammatory disorder, comprising administering to a patient an effective amount of pharmaceutically acceptable bodies carrying an effective number of phosphate-containing groups presented or presentable on the surface of said bodies, the phosphate-containing groups comprising a plurality of phosphate-glycerol groups or groups convertible to such groups, to inhibit and/or reduce the progression of the acute inflammatory disorder, said bodies being of a size from about 20 nanometers (nm) to 500 micrometers (µm).
PCT/CA2004/001053 2003-07-21 2004-07-20 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition Ceased WO2005007169A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2004257375A AU2004257375A1 (en) 2003-07-21 2004-07-20 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
MXPA06000805A MXPA06000805A (en) 2003-07-21 2004-07-20 Acute inflammatory condition treatment.
EP04761575A EP1658086A2 (en) 2003-07-21 2004-07-20 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
US10/565,360 US20070238708A1 (en) 2003-07-21 2004-07-20 Acute Inflammatory Condition Treatment
JP2006520639A JP2006528136A (en) 2003-07-21 2004-07-20 Liposomes containing glycerol phosphate for the treatment of acute inflammatory conditions
BRPI0412882-6A BRPI0412882A (en) 2003-07-21 2004-07-20 use of an amount of pharmaceutically acceptable bodies that carry an effective number of phosphate-containing groups
EA200600297A EA200600297A1 (en) 2003-07-21 2004-07-20 TREATMENT OF ACUTE INFLAMMATORY CONDITION
CA002533084A CA2533084A1 (en) 2003-07-21 2004-07-20 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
IL173068A IL173068A0 (en) 2003-07-21 2006-01-10 Acute inflammatory condition treatment
NO20060820A NO20060820L (en) 2003-07-21 2006-02-20 Treatment of acute inflammatory condition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48907103P 2003-07-21 2003-07-21
US60/489,071 2003-07-21

Publications (2)

Publication Number Publication Date
WO2005007169A2 WO2005007169A2 (en) 2005-01-27
WO2005007169A3 true WO2005007169A3 (en) 2005-09-22

Family

ID=34079469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/001053 Ceased WO2005007169A2 (en) 2003-07-21 2004-07-20 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition

Country Status (15)

Country Link
US (1) US20070238708A1 (en)
EP (1) EP1658086A2 (en)
JP (1) JP2006528136A (en)
KR (1) KR20060037369A (en)
CN (1) CN1826123A (en)
AU (1) AU2004257375A1 (en)
BR (1) BRPI0412882A (en)
CA (1) CA2533084A1 (en)
EA (1) EA200600297A1 (en)
IL (1) IL173068A0 (en)
MA (1) MA28002A1 (en)
MX (1) MXPA06000805A (en)
NO (1) NO20060820L (en)
WO (1) WO2005007169A2 (en)
ZA (1) ZA200601458B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131329A1 (en) * 2006-05-12 2007-11-22 Vasogen Ireland Limited Treatment of ubiquitin-proteasome system dysfunction related disorders
EP2142196A4 (en) 2007-03-29 2010-06-30 Nat Jewish Health SURFACTANT LIPIDS, COMPOSITIONS AND USE THEREOF
CN105434354A (en) * 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 Formulations for the treatment of deep tissue pain
US20120232034A1 (en) * 2009-08-21 2012-09-13 Henk-Andre Kroon Vesicular formulations
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
ES2879383T3 (en) 2015-06-30 2021-11-22 Sequessome Tech Holdings Limited Mixed formulas

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262405A (en) * 1990-02-20 1993-11-16 Synthelabo Method of improving bronchial mucus transport
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
WO2003061667A1 (en) * 2002-01-21 2003-07-31 Vasogen Ireland Limited Pharmaceutically acceptable phosphate-glycerol carrying bodies
WO2003086351A1 (en) * 2002-04-05 2003-10-23 Esperion Luv Development, Inc. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
WO2004024123A1 (en) * 2002-09-16 2004-03-25 Vasogen Ireland Limited Accelerating recovery from trauma
WO2004037270A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
DE10255106A1 (en) * 2002-11-24 2004-06-09 Novosom Ag Liposomal glucocorticoids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346526C2 (en) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
EP1248628A4 (en) * 1999-12-14 2004-08-04 Sky High Llc Phospholipid compositions as anti-inflammation agents
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262405A (en) * 1990-02-20 1993-11-16 Synthelabo Method of improving bronchial mucus transport
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
WO2003061667A1 (en) * 2002-01-21 2003-07-31 Vasogen Ireland Limited Pharmaceutically acceptable phosphate-glycerol carrying bodies
WO2003086351A1 (en) * 2002-04-05 2003-10-23 Esperion Luv Development, Inc. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
WO2004024123A1 (en) * 2002-09-16 2004-03-25 Vasogen Ireland Limited Accelerating recovery from trauma
WO2004037270A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
DE10255106A1 (en) * 2002-11-24 2004-06-09 Novosom Ag Liposomal glucocorticoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MYERS S I ET AL: "DECREASES PHOSPHATIDYLGLYCEROL AND INCREASED LYSOLECITHIN ARE INVOLVED IN EARLY RABBIT GALLBLADDER GB INFLAMMATION", GASTROENTEROLOGY, vol. 98, no. 5 PART 2, 1990, & 91ST ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION AND DIGESTIVE DISEASE WEEK, SAN, pages A256, XP008038482, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
KR20060037369A (en) 2006-05-03
MXPA06000805A (en) 2006-04-18
EP1658086A2 (en) 2006-05-24
AU2004257375A1 (en) 2005-01-27
US20070238708A1 (en) 2007-10-11
MA28002A1 (en) 2006-07-03
IL173068A0 (en) 2006-06-11
BRPI0412882A (en) 2006-10-03
CA2533084A1 (en) 2005-01-27
EA200600297A1 (en) 2006-08-25
ZA200601458B (en) 2007-05-30
JP2006528136A (en) 2006-12-14
CN1826123A (en) 2006-08-30
WO2005007169A2 (en) 2005-01-27
NO20060820L (en) 2006-04-10

Similar Documents

Publication Publication Date Title
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
DE69930158D1 (en) METHOD FOR PRODUCING PARTICLES WITH A AREA CONVERTED FROM THE AMORPH AND / OR METASTABILES CRYSTALLINE CONDITION TO A CRYSTALLINE CONDITION
FI964789A0 (en) Pefluoroalkyl ketone inhibitors of elastase and processes for their preparation
AU6586896A (en) Fatty acid treatment
EP1466606A3 (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
SE9504537D0 (en) Ways of treating and diagnosing respiratory disorders during sleep and means of performing the method
AU6143794A (en) Use of riluzole for treating aids-related neural disorders
EP1284257A3 (en) Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO2025024305A3 (en) Irak4 degraders and uses thereof
WO1998036730A3 (en) Compositions for treating acne rosacea
MXPA05012320A (en) Treatment of bipolar disorders and associated symptoms.
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
DE50310916D1 (en) COSMETIC AND DERMATOLOGICAL AGENT WITH MAGNETIC PARTICLES, THE PRODUCTION AND THEIR USE
CA2200126A1 (en) Treatment and prophylaxis of pancreatitis
MXPA05007389A (en) Method of treating cognitive decline due to sleep deprivation and stress.
NO20060820L (en) Treatment of acute inflammatory condition
WO2003032910A3 (en) Carbinols for the treatment of neuropathic dysfunction
EP0744176A3 (en) Methods for inhibiting bone loss
DE69920033D1 (en) METHOD FOR REDUCING CANCER SYMPTOMS
AU5972994A (en) Formed piece particularly for use as packing material, method and apparatus for its manufacture and use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480021287.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020067001122

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2533084

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12006500154

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000805

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006520639

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004761575

Country of ref document: EP

Ref document number: 545423

Country of ref document: NZ

Ref document number: 2004257375

Country of ref document: AU

Ref document number: 200601458

Country of ref document: ZA

Ref document number: 843/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1200600268

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200600297

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2004257375

Country of ref document: AU

Date of ref document: 20040720

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004257375

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067001122

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004761575

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0412882

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10565360

Country of ref document: US

Ref document number: 2007238708

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10565360

Country of ref document: US